(Q36458462)

14 August 2017

1 reference

title

Bexarotene in the treatment of cutaneous T-cell lymphoma (English)

1 reference

14 August 2017

Christiane Querfeld

1

1 reference

14 August 2017

Lakshmi V Nagelli

2

1 reference

14 August 2017

Steven T Rosen

3

1 reference

14 August 2017

Timothy M Kuzel

4

1 reference

14 August 2017

Joan Guitart

5

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 May 2006

1 reference

Expert Opinion on Pharmacotherapy

14 August 2017

1 reference

14 August 2017

7

1 reference

14 August 2017

7

1 reference

14 August 2017

907-915

1 reference

WHO-EORTC classification for cutaneous lymphomas

14 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.907

Primary cutaneous lymphomas: a review with current treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.907

A human retinoic acid receptor which belongs to the family of nuclear receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.907

RAR-RXR selectivity and biological activity of new retinoic acid analogues with heterocyclic or polycyclic aromatic systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.907

Keratinocyte differentiation is stimulated by activators of the nuclear hormone receptor PPARalpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.907

Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.907

Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.907

The nuclear receptor superfamily: the second decade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.907

Recent developments in receptor-selective retinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.907

Lack of apoptosis of Sézary cells in the circulation following oral bexarotene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.907

Biological effects of bexarotene in cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.907

Retinoids--which dermatological indications will benefit in the near future?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.907

Use of retinoic acids in the treatment of peripheral T-cell lymphoma: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.907

Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.907

Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.907

Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.907

Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.907

Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.907

Optimizing bexarotene therapy for cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.907

Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous t-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.907

Oral bexarotene in a therapy-resistant Sézary syndrome patient: observations on Sézary cell compartmentalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.907

Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: development of extracutaneous lymphoma in 6 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.907

Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.907

Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.907

Bexarotene is a new treatment option for lymphomatoid papulosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.907

Response of CD30+ large cell lymphoma of skin to bexarotene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.907

Regression of multifocal, skin-restricted, CD30-positive large T-cell lymphoma with interferon alfa and bexarotene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.907

Retinoids increase human apo C-III expression at the transcriptional level via the retinoid X receptor. Contribution to the hypertriglyceridemic action of retinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.907

Roferon-A in combination with Tigason in cutaneous T-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.907

Combined treatment with oral etretinate and electron beam therapy in patients with cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.907

Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.907

The addition of interferon gamma to oral bexarotene therapy with photopheresis for Sézary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.907

Treatment of mycosis fungoides with bexarotene and psoralen plus ultraviolet A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.907

A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.907

Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.907

The novel synthetic oleanane triterpenoid CDDO (2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid) induces apoptosis in Mycosis fungoides/Sézary syndrome cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.907

21 January 2018

Identifiers

DOI

10.1517/14656566.7.7.907

1 reference

14 August 2017

1 reference